Salix   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Sunnvale CA United States (1989)
Status: Acquired by Bausch Health Companies (2015)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1989
chlorothiazide (diuril)
First NDA Approval
2000
balsalazide (colazal)
Last Known Activity
2018

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (20)

balsalazide (colazal) (2000 NDA)

budesonide (rhinocort) (2013)

chlorothiazide (diuril) (1961)

conestat alfa (Ruconest) (2014 NDA)

crofelemer (mytesi) (2012 NDA)

famotidine (pepcid) (1987)

fenofibrate (fenoglide) (2007)

methylnaltrexone (relistor) (2008)

metoclopramide (reglan) (2009)

omeprazole (prilosec) (2004)

plecanatide (trulance) (2017)

polyethylene glycol 3350 (colyte) (2006)

potassium chloride (klor-con) (2006)

rifaximin (xifaxan) (2004 NDA)

sodium bicarbonate (2004)

sodium chloride (2006)

sodium phosphate (2000)

sodium sulfate (2018)

urea (1984)

vitamin c (2006)

Drugs in Phase 3 Trials (1)

Key: Salix (0) Acquired (1)

methylene blue (proveblue) (2 trials)

Drugs in Phase 2 Trials (3)

Key: Salix (0) Acquired (3)

allogeneic adipose derived mesenchymal stem cell (1 trial)

cb-10-01 (1 trial)

rifamycin (aemcolo) (2 trials)

Drugs in Phase 1 Trials (1)

Key: Salix (0) Acquired (1)

transgenic lymphocyte immunization vaccine (1 trial)

Overview

  • Highest Phase:
  • # of Trials:
  • # of Trial APIs: